Idenix Pharmaceuticals (IDIX)

[DewDiligence]

HBV Market in Europe is Large and Poorly Penetrated

[See #msg-21746191 for info on the US HBV market, which is smaller than the European market but is also expanding rapidly.]

In Europe, there are 9M people with chronic HBV infection, of whom only 25% are diagnosed.

Only 15% of those who are diagnosed are currently treated. In other words, only 4% (.25x.15) of Europeans with chronic HBV are currently treated.

France, Spain, and Italy are especially large, untapped markets.

(Source: GILD 2Q07 CC)